EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma

Marianne Baastrup Soendergaard iD, Frederikke Hjortdahl, Susanne Hansen iD, Anne-Sofie Bjerrum, Anna von Bülow iD, Ole Hilberg iD, Barbara Bonnesen Bertelsen, Claus Rikard Johnsen, Sofie Lock-Johansson, Roxana Vijdea, Linda Makowska Rasmussen, Johannes Martin Schmid und 3 weitere

European Respiratory Journal · 2025-04 · 65 (4) · 2401497

DOI: 10.1183/13993003.01497-2024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 09.01.2025. Verfasst von Marianne Baastrup Soendergaard und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Copenhagen University Hospital - Bispebjerg, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents, Biological Products. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologics can induce remission in some patients with severe asthma; however, little is known about pre-biologic disease trajectories and their association with outcomes from biological treatment. We aimed to identify long-term trajectories of disease progression in patients initiating biologics and investigate trajectory associations with disease burden and impact on biologic therapy efficacy.

Methods

Patients in the Danish Severe Asthma Register initiating biologic therapy between 2016 and 2022 were included and followed retrospectively in prescription databases starting 1995. We performed sequence analysis for inhaled corticosteroid treatment intensity over time combined with unsupervised trajectory clustering.

Results

In total, 755 patients were included and three pre-biologic disease trajectories were identified: “Chronic severe asthma” (26%), “Gradual onset severe asthma” (35%) and “Recent, sudden onset severe asthma” (39%). “Chronic severe asthma” patients were older, had the longest disease duration (35 years), the most impaired pulmonary function, the highest comorbidity prevalence and the lowest employment rate. “Recent, sudden onset severe asthma” patients were younger, had shorter disease duration (5 years), more tobacco exposure and the least impaired lung function. “Gradual onset severe asthma” patients had an intermediate burden of disease. The “ Chronic severe asthma” cluster demonstrated the lowest prevalence of remission (17%) compared to the “Gradual onset severe asthma” (29%) and “Recent, sudden onset severe asthma” (32%) clusters.

Conclusions

Three pre-biologic disease trajectories were identified, with increased disease duration and activity associating with asthma and comorbidity burden. Early intervention may be key to prevent irreversible adverse outcomes for patients with severe asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAnti-Asthmatic AgentsBiological ProductsHumansMaleFemaleMiddle AgedAdultRetrospective StudiesDisease ProgressionDenmarkSeverity of Illness IndexAgedRegistriesTreatment OutcomeAdrenal Cortex Hormones

Substanzen

Anti-Asthmatic AgentsBiological ProductsAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Copenhagen University Hospital - Bispebjerg, Copenhagen, Denmark.
  • M.B. Soendergaard and F. Hjortdahl contributed equally to this work.
  • Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.
  • Sygehus Lillebaelt - Vejle Sygehus, Vejle, Denmark.
  • Department of Respiratory Medicine, Copenhagen University Hospital - Gentofte, Hellerup, Denmark.
  • Allergy Clinic, Copenhagen University Hospital - Gentofte, Hellerup, Denmark.

ORCID-Profile: Marianne Baastrup Soendergaard, Susanne Hansen, Anna von Bülow, Ole Hilberg, Charlotte Suppli Ulrik, Kjell Erik Julius Håkansson

Zitieren

APA

Soendergaard, M. B., Hjortdahl, F., Hansen, S., Bjerrum, A. S., von Bülow, A., Hilberg, O., Bonnesen Bertelsen, B., Johnsen, C. R., Lock-Johansson, S., Vijdea, R., Rasmussen, L. M., Schmid, J. M., Ulrik, C. S., Porsbjerg, C., & Håkansson, K. E. J. (2025). Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma. European Respiratory Journal, 65(4), 2401497. https://doi.org/10.1183/13993003.01497-2024

Vancouver

Soendergaard MB, Hjortdahl F, Hansen S, Bjerrum AS, von Bülow A, Hilberg O, et al. Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma. European Respiratory Journal. 2025;65(4):2401497. doi:10.1183/13993003.01497-2024

BibTeX
@article{Soendergaard2025,
  author = {Soendergaard, Marianne Baastrup and Hjortdahl, Frederikke and Hansen, Susanne and Bjerrum, Anne-Sofie and von Bülow, Anna and Hilberg, Ole and Bonnesen Bertelsen, Barbara and Johnsen, Claus Rikard and Lock-Johansson, Sofie and Vijdea, Roxana and Rasmussen, Linda Makowska and Schmid, Johannes Martin and Ulrik, Charlotte Suppli and Porsbjerg, Celeste and Håkansson, Kjell Erik Julius},
  title = {Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma},
  journal = {European Respiratory Journal},
  year = {2025},
  volume = {65},
  number = {4},
  pages = {2401497},
  doi = {10.1183/13993003.01497-2024}
}
Kostenlos starten →